JenaValve Technology, Inc., a developer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, raised $62.5m in a Series C venture round.
Backers included Gimv (GIMB.EN), Beijing-based Legend Capital, Omega Funds, Edmond de Rothschild Investment Partners, Atlas Venture Fund, NeoMed Management, VI Partners AG and Sunstone Capital A/S.
The company intends to use the funds for clinical trials, expansion of commercial infrastructure, pursue clinical initiatives in the US as well as pursue regulatory approval for its TAVI product in China.
Founded in 2006 and led by Helmut J. Straubiger, CEO, JenaValve Technology is a U.S. corporation (Wilmington, Del.) with primary operations in Munich, Germany, which develops, manufactures and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease.
The company’s transapical aortic valve system is CE marked and currently marketed in Europe and other markets worldwide.